Immunome, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $177.3M | $129.5M | $23.1M |
| SG&A Expense | $43.8M | $33.0M | $19.7M |
| Operating Income | $-224.1M | $-305.8M | $-109.5M |
| Operating Margin | -3,228.8% | -3,382.4% | -781.4% |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-212.4M | $-293.0M | $-106.8M |
| Net Margin | -3,060.0% | -3,240.4% | -761.9% |
| EPS (Basic) | $-2.43 | $-5.00 | $-1.79 |
| EPS (Diluted) | $-2.43 | $-5.00 | $-1.79 |
| Shares Outstanding (Basic) | 87.4M | 58.6M | 59.5M |
| Shares Outstanding (Diluted) | 87.4M | 58.6M | 59.5M |
| Dividends Per Share | — | — | — |